The domino effect triggered by the tethered ligand of the protease activated receptors
- 3 August 2020
- journal article
- review article
- Published by Elsevier BV in Thrombosis Research
- Vol. 196, 87-98
- https://doi.org/10.1016/j.thromres.2020.08.004
Abstract
Protease activated receptors (PARs) are G-protein coupled receptors (GPCRs) that have a unique activation mechanism. Unlike other GPCRs that can be activated by free ligands, under physiological conditions, PARs are activated by the tethered ligand, which is a part of their N-terminus that is unmasked by proteolysis. It has been 30 years since the first member of the family, PAR1, was identified. In this review, we will discuss this unique tethered ligand mediate receptor activation of PARs in detail: how they interact with the proteases, the complex structural rearrangement of the receptors upon activation, and the termination of the signaling. We also summarize the structural studies of the PARs and how single nucleotide polymorphisms impact the receptor reactivity. Finally, we review the current strategies for inhibiting PAR function with therapeutic targets for anti-thrombosis. The focus of this review is PAR1 and PAR4 as they are the thrombin signal mediators on human platelets and therapeutics targets. We also include the structural studies of PAR2 as it informs the mechanism of action for PARs in general.Keywords
Funding Information
- National Institutes of Health (HL098217)
- American Heart Association (18PRE33960396)
- Schwab Charitable Fund
This publication has 150 references indexed in Scilit:
- Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigenProceedings of the National Academy of Sciences of the United States of America, 2013
- High-resolution crystal structure of human protease-activated receptor 1Nature, 2012
- ALIX binds a YPX3L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sortingThe Journal of cell biology, 2012
- Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonistBritish Journal of Pharmacology, 2011
- Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1Proceedings of the National Academy of Sciences of the United States of America, 2011
- Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseasesBritish Journal of Pharmacology, 2010
- Caveolae are required for protease-selective signaling by protease-activated receptor–1Proceedings of the National Academy of Sciences of the United States of America, 2009
- Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand SiteCell, 2009
- Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4Proceedings of the National Academy of Sciences of the United States of America, 2007
- Interaction of Thrombin with PAR1 and PAR4 at the Thrombin Cleavage SiteBiochemistry, 2007